COHERUS ONCOLOGY INC (CHRS) Stock Price & Overview
NASDAQ:CHRS • US19249H1032
The current stock price of CHRS is 1.82 USD. Today CHRS is up by 3.41%. In the past month the price decreased by -12.92%. In the past year, price increased by 75%.
CHRS Key Statistics
- Market Cap
- 219.983M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.30
- Dividend Yield
- N/A
CHRS Stock Performance
CHRS Stock Chart
CHRS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CHRS. When comparing the yearly performance of all stocks, CHRS is one of the better performing stocks in the market, outperforming 94.21% of all stocks.
CHRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CHRS. Both the profitability and financial health of CHRS have multiple concerns.
CHRS Earnings
On November 6, 2025 CHRS reported an EPS of -0.33 and a revenue of 11.57M. The company beat EPS expectations (0.45% surprise) and missed revenue expectations (-15.42% surprise).
CHRS Forecast & Estimates
12 analysts have analysed CHRS and the average price target is 5.78 USD. This implies a price increase of 217.58% is expected in the next year compared to the current price of 1.82.
For the next year, analysts expect an EPS growth of -95.39% and a revenue growth -83.13% for CHRS
CHRS Groups
Sector & Classification
CHRS Financial Highlights
Over the last trailing twelve months CHRS reported a non-GAAP Earnings per Share(EPS) of -1.3. The EPS decreased by -19.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 185.44% | ||
| ROA | 30% | ||
| ROE | 176.56% | ||
| Debt/Equity | 0.58 |
CHRS Ownership
CHRS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CHRS
Company Profile
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 161 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
Company Info
COHERUS ONCOLOGY INC
333 Twin Dolphin Dr, Suite 600, 201 Redwood Shores Parkway, Suite 200
Redwood City CALIFORNIA 94065 US
CEO: Dennis M. Lanfear
Employees: 161
Phone: 13026587581
COHERUS ONCOLOGY INC / CHRS FAQ
What does COHERUS ONCOLOGY INC do?
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 161 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
What is the stock price of COHERUS ONCOLOGY INC today?
The current stock price of CHRS is 1.82 USD. The price increased by 3.41% in the last trading session.
What is the dividend status of COHERUS ONCOLOGY INC?
CHRS does not pay a dividend.
What is the ChartMill technical and fundamental rating of CHRS stock?
CHRS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for COHERUS ONCOLOGY INC?
COHERUS ONCOLOGY INC (CHRS) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for COHERUS ONCOLOGY INC?
COHERUS ONCOLOGY INC (CHRS) has a market capitalization of 219.98M USD. This makes CHRS a Micro Cap stock.